Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 4;9(4):e12426.
doi: 10.1002/trc2.12426. eCollection 2023 Oct-Dec.

Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions

Barry D Greenberg  1 , Cynthia A Lemere  2 , Lisa L Barnes  3 , Kathleen M Hayden  4 , Walter A Kukull  5 , Esther S Oh  6 , Peter J Snyder  7 , Mark Supiano  8 , Peggye Dilworth-Anderson  9
Affiliations
Editorial

Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions

Barry D Greenberg et al. Alzheimers Dement (N Y). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

BDG is Editor in Chief, Alzheimer's & Dementia: Translational Research and Clinical Interventions. CAL is SAB/Consultant for Acumen Pharmaceuticals, Biogen, Sanofi Genzyme, and unpaid advisor as an alumni of the Alzheimer's Association's Medical and Scientific Advisory Group. MS serves on the American Geriatrics Society Board of Directors. WAK is Director, National Alzheimer's Coordinating Center. No relevant funding or conflicts of interests pertaining to this editorial exist for any of the co‐authors.

References

    1. Van Dyck CH, Swanson CJ, Aisen RJ, et al. Lecanemab in early Alzheimer's disease, N Engl J Med. 2023;388:9‐21. doi:10.1056/NEJMoa2212948 - DOI - PubMed
    1. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197‐210. doi:10.14283/jpad.2022.30 - DOI - PubMed
    1. Sims JR, Zimmer JA, Evans CD, et al; for the TRAILBLAZER‐ALZ2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial. JAMA. Published online 2023. doi:10.1001/jama.2023.13239 - DOI - PMC - PubMed
    1. Hill CV, Pérez‐Stable EJ, Anderson NA, Bernard MA. The national institute on aging health disparities research framework. Ethnicity Disease. 2015;25(3):245. - PMC - PubMed
    1. Balls‐Berry JE, Babulal GM. Health disparities in dementia. Continuum. 2022;28(3):872‐884. - PMC - PubMed

Publication types

LinkOut - more resources